Drug therapy: Disorders of neuromuscular transmission caused by drugs
Related Experiment Videos
The New England Journal of Medicine
|August 23, 1979
Abstract
No abstract available in PubMed .
Related Concept Videos
Articles linked to this work by shared authors, journal, and citation graph.
EAN 2024 Guideline on the Diagnostic Approach to Oligo/Asymptomatic HyperCKemia.
European journal of neurology·2026
Statins and the neuromuscular system: a neurologist's perspective.
European journal of neurology·2014
Cytokines in immune-mediated inflammatory myopathies: cellular sources, multiple actions and therapeutic implications.
Clinical and experimental immunology·2014
EFNS/ENS Guidelines for the treatment of ocular myasthenia.
European journal of neurology·2014
Statin myotoxicity: a review of genetic susceptibility factors.
Neuromuscular disorders : NMD·2013
In Vitro Fertilization or Intrauterine Insemination in Unexplained Infertility.
The New England journal of medicine·2026
Gram-Negative Bacterial Resistance.
The New England journal of medicine·2026
Tarlatamab-Durvalumab Maintenance for Extensive-Stage Small-Cell Lung Cancer.
The New England journal of medicine·2026
Sacituzumab Tirumotecan plus Pembrolizumab in PD-L1-Negative Advanced NSCLC.
The New England journal of medicine·2026
Causative factors and outcomes of pyogenic granulomas presenting to a hospital eye clinic.
Clinical & experimental optometry·2026
Meta-Analysis: Potassium-Competitive Acid Blockers Versus Proton Pump Inhibitors for Gastroprotection in Patients Receiving Antiplatelet Therapy.
Alimentary pharmacology & therapeutics·2026
Current practices, challenges, and future directions in subcutaneous oncology monoclonal antibody delivery: a qualitative study.
Expert opinion on drug delivery·2026
Ensuring patient rights, safety, and welfare in "compassionate use" of drugs.
Perspectives in clinical research·2026
Pediatric obesity pharmacotherapy: a practical guide for general pediatricians.
Current opinion in pediatrics·2026
Old Drugs, New Targets: Molecular Docking Insights into Repurposing Proton Pump Inhibitors for the TLR4/MD-2, NLRP3, and C5aR1 Axes in Autoimmune Liver Diseases.
Pharmaceuticals (Basel, Switzerland)·2026